Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Sertoli cells show promise for therapeutics

12.07.2011
Two papers published in the current issue of Cell Transplantation (20:5), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, highlight the therapeutic potential of human Sertoli cells that are present in the testes and are also called "nurse" or "mother" cells because they nurture the developing sperm cells.

Sertoli cells form the blood-testes barrier that separates the blood compartment of the testes from the compartment of the seminiferous tubules. Once differentiated to form the blood-testes barrier, Sertoli cells do not proliferate, although recent research has been aimed at growing Sertoli cells outside of the body.

Determining Sertoli cell functionality in vitro

A team of U.S. and Argentina-based researchers reporting on isolating and characterizing Sertoli cells from deceased human organ/tissue donors report on techniques by which Sertoli cells "proliferated readily" in vitro under "optimized conditions" with a four day "doubling time."

"Since there is interest in using Sertoli cells to minimize transplant rejection due to their immunological suppressive properties, establishing conditions to produce proliferative human Sertoli cells in vitro could facilitate research on their use for therapeutic applications in cell or organ transplantation," said study corresponding author Dr. Constance M. John of San Francisco-based MandalMed, Inc. "In this study we aimed to isolate and expand primary adult human Sertoli cells from cadaveric testes and characterize them to determine their functionality in vitro."

The researchers found that expanded, cryopreserved Sertoli cells could retain their characteristic markers and exhibited prototype functionality to establish a tight junction barrier.

"The cells provided evidence of potential utility in spermatogenesis and infertility research and reproductive toxicology," concluded the researchers. "Because of their robust proliferative activity and unique biological role, the primary Sertoli cells could have cell therapy applications."

Contact: Dr. Constance M. John, MandalMed, Inc. 665 3rd St. Suite 250,
San Francisco, CA 94107
Tel. (415) 495-5570
Fax. (415) 495- 5575
Email: constancejohn@mandalmed.com
Citation: Chui, K. ; Trivedi, A. ; Cheng, C. Y.; Cherbavaz, D. B.; Dazin, P. F. ; Huynh, A. L. T.; Mitchell, J. B.; Rabinovich, G. A.; Noble-Haeusslein, L. J.; John, C. M. Characterization and Functionality of Proliferative Human Sertoli Cells. Cell Transplant. 20(5):619-635;_2011.

Sertoli cells successfully deliver therapeutics deep into the lung

In a study seeking a better way to get medication to lower lung areas, such as to the alveoli and other areas difficult to reach and in which to retain therapeutics, University of South Florida (USF) researchers report that rat Sertoli cells loaded with chitosan nanoparticles and coupled with an anti-inflammatory compound, injected into the tails of mice with deep inflammation, reached the deep areas of the lung quickly and stayed active.

Current lung therapy techniques, such as aerosols, nebulizer mists, Metered Dose Inhalers and other means have proven largely ineffective because of airway obstructions, mucus, and airway edema that often prevent inhaled delivery. Even when these therapeutics are delivered effectively, they are often quickly expelled during exhalation and the drug is not in the lung long enough for sustained release.

"A novel way to deliver nanoparticles coupled with drugs to the deep lung is to utilize a bio-compatible cell-based system and deliver therapy through the peripheral vasculature instead of a pulmonary route," said corresponding author Dr. Donald F. Cameron of the University of South Florida (USF) Department of Pathology and Cell Biology.

The USF study tested the delivery of an anti-inflammatory compound to the deep lungs of animals modeled with pulmonary inflammation and found a "high therapeutic effect" 24 hours after drug delivery.

"The drug-loaded Sertoli cells became entrapped in the host animal's deep lung and was distributed around the alveoli while intact Sertoli cells were not detected in other tissues or organs," said Dr. Cameron. "At 15 minutes post injection, 92 percent of the labeled nanoparticle load in the injected Sertoli cells were present in the lungs with a minimal amount detected in the liver and kidney."

The researchers concluded that the use of pre-loaded Sertoli cells to deliver therapeutic nanoparticles to the lungs through the peripheral vasculature and subsequently migrated to the pulmonary vasculature, potentially providing an effective therapeutic alternative to current methodologies that have been proven less effective.

"These two studies describe a set of conditions for expanding human sertoli cells in vitro from deceased organ/tissue donors and a potential use for the cells (this time taken from rats)" said Dr. Camillo Ricordi, coeditor-in-chief of Cell Transplantation and Director of the Cell Transplant Center and Diabetes Research Institute at the University of Miami. "While the second paper covers the potential use of sertoli cells as vectors for the delivery of specific factors to the deep areas of the lung, these cells may also be beneficial as delivery systems for other disorders. This will require further investigation."

Contact: Dr. D.F. Cameron, MDC 11, Department of Pathology & Cell Biology, University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd. Tampa, FL 33612
Tel. (813) 974-9434
Fax. (813) 974-2058
Citation: Kumar, A.; Glam, M.; El-Badri, N.; Mohapatra, S.; Haller, E.; Park, S.; Patrick, L.; Nattkemper, L.; Vo, D.; Cameron, D. F. Initial Observations of Cell-Mediated Drug Delivery to the Deep Lung. Cell Transplant. 20(5):609-618; 2011.

The editorial offices for Cell Transplantation are at the Center of Excellence for Aging and Brain Repair, College of Medicine, the University of South Florida and the Diabetes Research Institute, University of Miami Miller School of Medicine. Contact, David Eve, PhD. at celltransplantation@gmail.com or Camillo Ricordi, MD at ricordi@miami.edu

News release by Randolph Fillmore, Florida Science Communications, www.sciencescribe.net

David Eve | EurekAlert!
Further information:
http://www.sciencescribe.net

More articles from Life Sciences:

nachricht Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)

nachricht CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>